Cookies on VetMed Resource

Like most websites we use cookies. This is to ensure that we give you the best experience possible.

 

Continuing to use www.cabi.org  means you agree to our use of cookies. If you would like to, you can learn more about the cookies we use.

VetMed Resource

Veterinary information to support practice, based on evidence and continuing education

Sign up to receive our Veterinary & Animal Sciences e-newsletter, book alerts and offers direct to your inbox.

Results per page:

Search results

Abstract

While current lymphoma therapies induce remission in most dogs, drug-resistant relapse is common, creating a need for novel agents. Rabacfosadine (RAB), a double prodrug of the acyclic nucleotide phosphonate 9-(2-phosphonylmethoxyethel) guanine (PMEG), preferentially targets lymphoma cells with...

Author(s)
Saba, C. F.; Clifford, C.; Burgess, K.; Phillips, B.; Vail, D.; Wright, Z.; Curran, K.; Fan, T.; Elmslie, R.; Post, G.; Thamm, D.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2020, 18, 4, pp 763-769
Abstract

Rabacfosadine (RAB), a novel double prodrug of the acyclic nucleotide phosphonate PMEG, preferentially targets neoplastic lymphocytes with reduced off target toxicity. Historical studies have suggested that every 21-day dosing is effective with acceptable toxicity. The purpose of this study was to...

Author(s)
Saba, C. F.; Vickery, K. R.; Clifford, C. A.; Burgess, K. E.; Phillips, B.; Vail, D. M.; Wright, Z. M.; Morges, M. A.; Fan, T. M.; Thamm, D. H.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2018, 16, 1, pp E76-E82
Abstract

Background: Rabacfosadine (RAB), a novel antineoplastic agent conditionally licensed for the treatment of lymphoma in dogs, is efficacious in both naïve and previously treated dogs. Its use in combination with L-asparaginase (L-ASP) has not been studied. Hypothesis/Objectives: To evaluate the...

Author(s)
Cawley, J. R.; Wright, Z. M.; Meleo, K.; Post, G. S.; Clifford, C. A.; Vickery, K. R.; Vail, D. M.; Bergman, P. J.; Thamm, D. H.
Publisher
Wiley, Boston, USA
Citation
Journal of Veterinary Internal Medicine, 2020, 34, 2, pp 882-889
Abstract

We report a precision medicine platform that evaluates the probability of chemotherapy drug efficacy for canine lymphoma by combining ex vivo chemosensitivity and immunophenotyping assays with computational modelling. We isolated live cancer cells from fresh fine needle aspirates of affected lymph...

Author(s)
Bohannan, Z.; Pudupakam, R. S.; Koo JaMin; Horwitz, H.; Tsang, J.; Polley, A.; Han EnYang [Han, E. Y. J.]; Fernandez, E.; Park, S.; Swartzfager, D.; Qi SeahXi [Qi, S. X. N.]; Tu, C.; Rankin, W. V.; Thamm, D. H.; Lee HyeRyeon; Lim SungWon
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2020, 19, 1, pp 160-171
Abstract

Background: Standard of care treatment for multicentric lymphoma in dogs remains doxorubicin (DOX)-based combination chemotherapy, but owners may hesitate to commit the time and financial resources to complete such a protocol, typically requiring 12-16 visits. Rabacfosadine (RAB), a double prodrug...

Author(s)
Thamm, D. H.; Vail, D. M.; Post, G. S.; Fan, T. M.; Phillips, B. S.; Axiak-Bechtel, S.; Elmslie, R. S.; Klein, M. K.; Ruslander, D. A.
Publisher
Wiley, Boston, USA
Citation
Journal of Veterinary Internal Medicine, 2017, 31, 3, pp 872-878
Abstract

The term lymphoma encompasses a heterogeneous group of neoplasms originating from the lymphoreticular cells. It is the most common lymphoproliferative disorder in dogs and one of the most common tumours seen in this species. In recent years, significant changes have been seen in the veterinary...

Author(s)
Verganti, S.; Berlato, D.
Publisher
Veterinary Business Development Ltd, Peterborough, UK
Citation
Veterinary Times, 2018, 48, 31, pp 13-15

Refine Results

Sort Order
Author
Subject Topics